If Lympro sells for several hundred million a year from now, why wouldn't Gerald do that in order to pay for the development of MANF? Gerald has publicly talked about entertaining bids from pharma after it commercializes. Did you miss that? We are a "holding company" where we buy an asset in distress, improve it, and then sell it at a higher value. This is pretty widely known, Easy Money.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links